M Manns, G Gerken, C Trautwein, M Meuer, T Porally, H P Dienes, K H Meyer zum Büschenfelde
{"title":"原发性胆汁性肝硬化(PBC)特异性线粒体决定因素的免疫印迹表征。","authors":"M Manns, G Gerken, C Trautwein, M Meuer, T Porally, H P Dienes, K H Meyer zum Büschenfelde","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Antimitochondrial antibodies (AMA) are detected in up to 100% of patients with primary biliary cirrhosis (PBC); subtypes of AMA are disease specific. Sera from 21 patients with PBC and from 50 patients with various hepatic and non-hepatic diseases were tested for AMA by indirect immunofluorescence, radioimmunoassay for PBC-specific subtype anti M2 and characterized by western blot analysis and agarose-IEF-immunoblotting. Sera from patients with PBC reacted with up to 7 different mitochondrial polypeptides on western blots, mol. wt. 24,000-62,000 dalton. Sera from 50 patients with various hepatic and non-hepatic diseases did not react with these polypeptides. Sera with other AMA subtypes were included in this study (anti M1, anti M3, and anti M5). These mitochondrial polypeptides were associated with inner mitochondrial membranes (mitoplasts). Sonification led to a solubilization of several mitochondrial polypeptides (p 62, p 48, p 40, p 24). On agarose-IEF-immunoblotting sera from patients with PBC and 3 sera from patients with AMA positive cholestatic CAH but no other sera reacted with a protein band at pI 4.0; seven PBC sera reacted in addition with a protein band at pI 4.4. Western blot and agarose-IEF-immunoblotting are sensitive and specific tools to identify and characterize mitochondrial target antigens in PBC. Furthermore these techniques allow to study the clinical relevance of the heterogeneity of AMA in cholestatic liver disease.</p>","PeriodicalId":11189,"journal":{"name":"Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten","volume":"47 2","pages":"59-66"},"PeriodicalIF":0.0000,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characterization of primary biliary cirrhosis (PBC) specific mitochondrial determinants by immunoblotting.\",\"authors\":\"M Manns, G Gerken, C Trautwein, M Meuer, T Porally, H P Dienes, K H Meyer zum Büschenfelde\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Antimitochondrial antibodies (AMA) are detected in up to 100% of patients with primary biliary cirrhosis (PBC); subtypes of AMA are disease specific. Sera from 21 patients with PBC and from 50 patients with various hepatic and non-hepatic diseases were tested for AMA by indirect immunofluorescence, radioimmunoassay for PBC-specific subtype anti M2 and characterized by western blot analysis and agarose-IEF-immunoblotting. Sera from patients with PBC reacted with up to 7 different mitochondrial polypeptides on western blots, mol. wt. 24,000-62,000 dalton. Sera from 50 patients with various hepatic and non-hepatic diseases did not react with these polypeptides. Sera with other AMA subtypes were included in this study (anti M1, anti M3, and anti M5). These mitochondrial polypeptides were associated with inner mitochondrial membranes (mitoplasts). Sonification led to a solubilization of several mitochondrial polypeptides (p 62, p 48, p 40, p 24). On agarose-IEF-immunoblotting sera from patients with PBC and 3 sera from patients with AMA positive cholestatic CAH but no other sera reacted with a protein band at pI 4.0; seven PBC sera reacted in addition with a protein band at pI 4.4. Western blot and agarose-IEF-immunoblotting are sensitive and specific tools to identify and characterize mitochondrial target antigens in PBC. Furthermore these techniques allow to study the clinical relevance of the heterogeneity of AMA in cholestatic liver disease.</p>\",\"PeriodicalId\":11189,\"journal\":{\"name\":\"Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten\",\"volume\":\"47 2\",\"pages\":\"59-66\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1987-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
在高达100%的原发性胆汁性肝硬化(PBC)患者中检测到抗线粒体抗体(AMA);AMA亚型是疾病特异性的。本文采用间接免疫荧光法检测21例PBC患者和50例各种肝脏和非肝脏疾病患者血清中AMA的含量,用PBC特异性抗M2亚型放射免疫法检测,并用western blot分析和琼脂糖- ief免疫印迹法检测。PBC患者的血清在western blots上与多达7种不同的线粒体多肽反应,摩尔重量为24,000-62,000道尔顿。50例各种肝脏和非肝脏疾病患者的血清对这些多肽没有反应。其他AMA亚型血清(抗M1、抗M3和抗M5)也被纳入本研究。这些线粒体多肽与线粒体内膜(有丝分裂体)有关。超声导致了几种线粒体多肽的溶解(p 62, p 48, p 40, p 24)。PBC患者的琼脂糖- ief免疫印迹血清和AMA阳性的胆汁淤积CAH患者的血清,但没有其他血清与pI 4.0的蛋白带反应;7种PBC血清在pI 4.4处与蛋白带发生反应。Western blot和琼脂糖- ief免疫印迹是鉴定和表征PBC线粒体靶抗原的敏感和特异性工具。此外,这些技术允许研究AMA在胆汁淤积性肝病异质性的临床相关性。
Characterization of primary biliary cirrhosis (PBC) specific mitochondrial determinants by immunoblotting.
Antimitochondrial antibodies (AMA) are detected in up to 100% of patients with primary biliary cirrhosis (PBC); subtypes of AMA are disease specific. Sera from 21 patients with PBC and from 50 patients with various hepatic and non-hepatic diseases were tested for AMA by indirect immunofluorescence, radioimmunoassay for PBC-specific subtype anti M2 and characterized by western blot analysis and agarose-IEF-immunoblotting. Sera from patients with PBC reacted with up to 7 different mitochondrial polypeptides on western blots, mol. wt. 24,000-62,000 dalton. Sera from 50 patients with various hepatic and non-hepatic diseases did not react with these polypeptides. Sera with other AMA subtypes were included in this study (anti M1, anti M3, and anti M5). These mitochondrial polypeptides were associated with inner mitochondrial membranes (mitoplasts). Sonification led to a solubilization of several mitochondrial polypeptides (p 62, p 48, p 40, p 24). On agarose-IEF-immunoblotting sera from patients with PBC and 3 sera from patients with AMA positive cholestatic CAH but no other sera reacted with a protein band at pI 4.0; seven PBC sera reacted in addition with a protein band at pI 4.4. Western blot and agarose-IEF-immunoblotting are sensitive and specific tools to identify and characterize mitochondrial target antigens in PBC. Furthermore these techniques allow to study the clinical relevance of the heterogeneity of AMA in cholestatic liver disease.